{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:50:49Z","timestamp":1792439449551,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Cardiogenic shock (CS) is one of the leading causes of mortality in patients with acute cardiac disease, and systemic inflammation plays a critical role in its pathophysiology. This review explores the role of interleukin-6 (IL-6) in CS, with a focus on its biological pathways, prognostic value, and potential as a therapeutic target, highlighting the importance of addressing inflammation in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent evidence highlights systemic inflammation implied in CS progression. Among the various cytokines involved, IL-6 is a major pro-inflammatory cytokine associated with organ dysfunction, and high mortality rates in acute myocardial infarction complicated by CS. Mechanistic studies exhibited an involvement of IL-6 since the first stages of CS onset, suggesting its role as both a biomarker and likely a mediator of CS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>IL-6 emerges as a key inflammatory mediator in CS pathophysiology, serving as a prognostic biomarker and a potential therapeutic target. Future research should focus on further understanding the underlying mechanism linking acute inflammation and CS, patient phenotyping, and optimizing anti-inflammatory strategies investigating IL-6-targeted therapies to improve outcomes in this poor prognosis condition. Clinical trials of IL-6 blockade in cardiogenic shock are lacking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-025-02273-0","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T08:17:22Z","timestamp":1756541842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interleukin-6 in Cardiogenic Shock"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-7435","authenticated-orcid":false,"given":"Luca","family":"Fazzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Golino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Castrichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Tersalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"16","key":"2273_CR1","first-page":"e232","volume":"136","author":"JN Diepen Sv, Katz","year":"2017","unstructured":"Diepen Sv, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: A scientific statement from the American heart association. Circulation. 2017;136(16):e232\u201368.","journal-title":"Circulation"},{"issue":"18","key":"2273_CR2","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1001\/jama.2021.18323","volume":"326","author":"MD Samsky","year":"2021","unstructured":"Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. Cardiogenic shock after acute myocardial infarction: A review. JAMA. 2021;326(18):1840\u201350.","journal-title":"JAMA"},{"key":"2273_CR3","doi-asserted-by":"crossref","unstructured":"Jentzer JC. Understanding Cardiogenic Shock Severity and Mortality Risk Assessment. Circulation: Heart Failure. 2020;13(9):e007568.","DOI":"10.1161\/CIRCHEARTFAILURE.120.007568"},{"issue":"15","key":"2273_CR4","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE M\u00f8ller","year":"2024","unstructured":"M\u00f8ller JE, Engstr\u00f8m T, Jensen LO, Eiskj\u00e6r H, Mangner N, Polzin A, et al. Microaxial flow pump or standard care in Infarct-Related cardiogenic shock. N Engl J Med. 2024;390(15):1382\u201393.","journal-title":"N Engl J Med"},{"issue":"14","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","volume":"389","author":"H Thiele","year":"2023","unstructured":"Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal life support in Infarct-Related cardiogenic shock. N Engl J Med. 2023;389(14):1286\u201397.","journal-title":"N Engl J Med"},{"key":"2273_CR6","doi-asserted-by":"crossref","unstructured":"Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock. JACC. 2025;85(16):1618-41.","DOI":"10.1016\/j.jacc.2025.02.018"},{"issue":"24","key":"2273_CR7","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1161\/01.CIR.0000075927.67673.F2","volume":"107","author":"JS Hochman","year":"2003","unstructured":"Hochman JS. Cardiogenic shock complicating acute myocardial infarction. Circulation. 2003;107(24):2998\u20133002.","journal-title":"Circulation"},{"key":"2273_CR8","doi-asserted-by":"publisher","first-page":"599511","DOI":"10.3389\/fimmu.2020.599511","volume":"11","author":"MJM Silvis","year":"2020","unstructured":"Silvis MJM, Kaffka Genaamd Dengler SE, Odille CA, Mishra M, van der Kaaij NP, Doevendans PA, et al. Damage-Associated molecular patterns in myocardial infarction and heart transplantation: the road to translational success. Front Immunol. 2020;11:599511.","journal-title":"Front Immunol"},{"issue":"5","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00392-011-0403-3","volume":"101","author":"R Prondzinsky","year":"2012","unstructured":"Prondzinsky R, Unverzagt S, Lemm H, Wegener NA, Schlitt A, Heinroth KM, et al. Interleukin-6, -7, -8 and\u2013\u200910 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012;101(5):375\u201384.","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"2273_CR10","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/01.CCM.0000228919.33620.D9","volume":"34","author":"A Geppert","year":"2006","unstructured":"Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2006;34(8):2035\u201342.","journal-title":"Crit Care Med"},{"issue":"5","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00392-007-0626-5","volume":"97","author":"M Debrunner","year":"2008","unstructured":"Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R, et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol. 2008;97(5):298\u2013305.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1038\/s41598-020-64702-0","volume":"10","author":"J Cuinet","year":"2020","unstructured":"Cuinet J, Garbagnati A, Rusca M, Yerly P, Schneider AG, Kirsch M, et al. Cardiogenic shock elicits acute inflammation, delayed eosinophilia, and depletion of immune cells in most severe cases. Sci Rep. 2020;10(1):7639.","journal-title":"Sci Rep"},{"issue":"14","key":"2273_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/archinte.165.14.1643","volume":"165","author":"S Kohsaka","year":"2005","unstructured":"Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165(14):1643\u201350.","journal-title":"Arch Intern Med"},{"issue":"4","key":"2273_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14712\/18059694.2019.103","volume":"44","author":"R Pudil","year":"2001","unstructured":"Pudil R, Krejsek J, Pidrman V, Gregor J, Tich\u00fd M, Bures J. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica (Hradec Kralove). 2001;44(4):149\u201351.","journal-title":"Acta Medica (Hradec Kralove)"},{"issue":"2","key":"2273_CR15","first-page":"e0637","volume":"4","author":"JC Jentzer","year":"2022","unstructured":"Jentzer JC, Bhat AG, Patlolla SH, Sinha SS, Miller PE, Lawler PR, et al. Concomitant sepsis diagnoses in acute myocardial Infarction-Cardiogenic shock: 15-Year National Temporal trends, management, and outcomes. Crit Care Explor. 2022;4(2):e0637.","journal-title":"Crit Care Explor"},{"issue":"9","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1097\/CCM.0b013e31828a67b2","volume":"41","author":"S van Diepen","year":"2013","unstructured":"van Diepen S, Vavalle JP, Newby LK, Clare R, Pieper KS, Ezekowitz JA, et al. The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. Crit Care Med. 2013;41(9):2080\u20137.","journal-title":"Crit Care Med"},{"key":"2273_CR17","doi-asserted-by":"crossref","unstructured":"Jentzer JC, Lawler PR, Diepen Sv, Henry TD, Menon V, Baran DA et al. Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. Circulation: Cardiovascular Quality and Outcomes. 2020;13(12):e006956.","DOI":"10.1161\/CIRCOUTCOMES.120.006956"},{"issue":"5","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1378\/chest.124.5.1885","volume":"124","author":"N Lim","year":"2003","unstructured":"Lim N, Dubois MJ, De Backer D, Vincent JL. Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest. 2003;124(5):1885\u201391.","journal-title":"Chest"},{"key":"2273_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519\u201350.","journal-title":"Annu Rev Immunol"},{"issue":"Suppl 1","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1002\/eji.200737772","volume":"37","author":"CA Dinarello","year":"2007","unstructured":"Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(Suppl 1):S34\u201345.","journal-title":"Eur J Immunol"},{"issue":"9","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"A Abbate","year":"2020","unstructured":"Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260\u201380.","journal-title":"Circ Res"},{"issue":"4","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","volume":"138","author":"M Akdis","year":"2016","unstructured":"Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138(4):984\u20131010.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2273_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265(3):621\u201336.","journal-title":"Biochem J"},{"issue":"6","key":"2273_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello Charles A, Mantovani A. The Interleukin-1 family: back to the future. Immunity. 2013;39(6):1003\u201318.","journal-title":"Immunity"},{"issue":"47","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"48487","DOI":"10.1074\/jbc.R400025200","volume":"279","author":"S Black","year":"2004","unstructured":"Black S, Kushner I, Samols D. C-reactive protein**. J Biol Chem. 2004;279(47):48487\u201390.","journal-title":"J Biol Chem"},{"issue":"9","key":"2273_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237\u201347.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"2273_CR27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/eurheartj\/ehr377","volume":"33","author":"S Selejan","year":"2012","unstructured":"Selejan S, P\u00f6ss J, Walter F, Hohl M, Kaiser R, Kazakov A, et al. Ischaemia-induced up-regulation of Toll-like receptor 2 in Circulating monocytes in cardiogenic shock. Eur Heart J. 2012;33(9):1085\u201394.","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"2273_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1538-7836.2007.02491.x","volume":"5","author":"JH Griffin","year":"2007","unstructured":"Griffin JH, Fern\u00e1ndez JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost. 2007;5(Suppl 1):73\u201380.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2273_CR29","first-page":"348","volume":"6","author":"B Fellner","year":"2017","unstructured":"Fellner B, Rohla M, Jarai R, Smetana P, Freynhofer MK, Egger F, et al. Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2017;6(4):348\u201358.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9","key":"2273_CR30","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/00003246-200209000-00007","volume":"30","author":"A Geppert","year":"2002","unstructured":"Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med. 2002;30(9):1987\u201394.","journal-title":"Crit Care Med"},{"issue":"3","key":"2273_CR31","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.ijcard.2013.01.004","volume":"168","author":"S van Diepen","year":"2013","unstructured":"van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, et al. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol. 2013;168(3):2127\u201333.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2273_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11239-016-1390-z","volume":"42","author":"S van Diepen","year":"2016","unstructured":"van Diepen S, Alemayehu WG, Zheng Y, Theroux P, Newby LK, Mahaffey KW, et al. Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. J Thromb Thrombolysis. 2016;42(3):376\u201385.","journal-title":"J Thromb Thrombolysis"},{"key":"2273_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2020.08.069","volume":"322","author":"A Kataja","year":"2021","unstructured":"Kataja A, Tarvasm\u00e4ki T, Lassus J, Sionis A, Mebazaa A, Pulkki K, et al. Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock - Insights from the cardshock study. Int J Cardiol. 2021;322:191\u20136.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2273_CR34","doi-asserted-by":"publisher","first-page":"R152","DOI":"10.1186\/cc11467","volume":"16","author":"RP Andri\u00e9","year":"2012","unstructured":"Andri\u00e9 RP, Becher UM, Frommold R, Tiyerili V, Schrickel JW, Nickenig G, et al. Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction. Crit Care. 2012;16(4):R152.","journal-title":"Crit Care"},{"issue":"6","key":"2273_CR35","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1097\/CCM.0b013e31819fe896","volume":"37","author":"R Jarai","year":"2009","unstructured":"Jarai R, Fellner B, Haoula D, Jordanova N, Heinz G, Karth GD, et al. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med. 2009;37(6):1837\u201344.","journal-title":"Crit Care Med"},{"issue":"24","key":"2273_CR36","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/eurheartj\/ehab110","volume":"42","author":"U Ceglarek","year":"2021","unstructured":"Ceglarek U, Schellong P, Rosolowski M, Scholz M, Willenberg A, Kratzsch J, et al. The novel Cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction. Eur Heart J. 2021;42(24):2344\u201352.","journal-title":"Eur Heart J"},{"issue":"8","key":"2273_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.31083\/j.rcm2508303","volume":"25","author":"S Wang","year":"2024","unstructured":"Wang S, Wang L, Du Z, Yang F, Hao X, Wang X, et al. Phenotyping refractory cardiogenic shock patients receiving Venous-Arterial extracorporeal membrane oxygenation using machine learning algorithms. Rev Cardiovasc Med. 2024;25(8):303.","journal-title":"Rev Cardiovasc Med"},{"issue":"15","key":"2273_CR38","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S, Sharma K, T\u00f8llefsen IM, Bendz B, et al. Randomized trial of Interleukin-6 receptor Inhibition in patients with acute ST-Segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"2273_CR39","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.053318","volume":"143","author":"MAS Meyer","year":"2021","unstructured":"Meyer MAS, Wiberg S, Grand J, Meyer ASP, Obling LER, Frydland M, et al. Treatment effects of Interleukin-6 receptor antibodies for modulating the systemic inflammatory response after Out-of-Hospital cardiac arrest (The IMICA Trial): A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial. Circulation. 2021;143(19):1841\u201351.","journal-title":"Circulation"},{"issue":"19","key":"2273_CR40","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehi292","volume":"26","author":"P Th\u00e9roux","year":"2005","unstructured":"Th\u00e9roux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J. 2005;26(19):1964\u201370.","journal-title":"Eur Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02273-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02273-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02273-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:40:03Z","timestamp":1781610003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02273-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02273-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"27 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"129"}}